Neoadjuvant immune-checkpoint blockade in resectable colon cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed.

1. JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors.Journal of experimental & clinical cancer research : CR · 2024
   Article
2. Neoadjuvant Versus Adjuvant Chemotherapy for Resectable Metastatic Colon Cancer in Non-academic and Academic Programs.The oncologist · 2023
   Article
3. Perioperative immune checkpoint inhibition for colorectal cancer: recent advances and future directions.Frontiers in immunology · 2023
   Review
4. The Role of the Microbiome on the Pathogenesis and Treatment of Colorectal Cancer.Cancers · 2022
   Review
5. Efficacy of an ALDH peptide-based dendritic cell vaccine targeting cancer stem cells.Cancer immunology, immunotherapy : CII · 2022
   Article
6. Neoadjuvant immunotherapy in primary and metastatic colorectal cancer.The British journal of surgery · 2021
   Review
7. [Tumor vaccination-strategies and time points].Der Internist · 2021
   Review
8. Texture Analysis of Fractional Water Content Images Acquired during PET/MRI: Initial Evidence for an Association with Total Lesion Glycolysis, Survival and Gene Mutation Profile in Primary Colorectal Cancer.Cancers · 2021
   Article

Corrections and comments

• Comment on
  Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.2020

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as